Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:
• intermediate-2 and high-risk myelodysplastic syndromes (MDS) per the International Prognostic Scoring System (IPSS),
• chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,
• acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, per World Health Organisation (WHO) classification,
• AML with >30% marrow blasts per the WHO classification.